Poxel Names New Chair to Strengthen Financial Oversight Amid Strategic Pivot
Event summary
- Laure-Hélène Mercier appointed Chair of Poxel’s Board of Directors on September 3, 2026, replacing Sophie Jacq Lapointe.
- Mercier brings 20+ years of biotech and financial markets experience, including CFO roles at Innate Pharma.
- Poxel recently sold PXL770 to Scynexis for up to $196M, including $8M upfront payment.
- Company aims to strengthen financial oversight and governance excellence amid challenging financial environment.
The big picture
Poxel’s leadership change comes as the company navigates a strategic pivot, having recently divested a key asset (PXL770) while advancing its MASH program. The appointment of Mercier signals a focus on financial discipline and governance excellence, critical for a clinical-stage biopharmaceutical company operating in a challenging financial environment. The move aligns with broader industry trends where biotechs are strengthening governance to attract investors amid volatile markets.
What we're watching
- Governance Dynamics
- How Mercier’s financial expertise will impact Poxel’s strategic direction and shareholder communications.
- Execution Risk
- Whether Poxel can sustain momentum from recent asset sales and clinical progress in MASH.
- Market Perception
- The pace at which investor confidence improves under the new governance structure.